$232 Million is the total value of DAFNA Capital Management LLC's 79 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NEOS | Exit | NEOS THERAPEUTICS INC | $0 | – | -27,500 | -100.0% | -0.02% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS INC | $0 | – | -54,569 | -100.0% | -0.09% | – |
| APTX | Exit | APTINYX INC | $0 | – | -14,500 | -100.0% | -0.12% | – |
| ADXS | Exit | ADVAXIS INC | $0 | – | -1,666,666 | -100.0% | -0.16% | – |
| LPTX | Exit | LEAP THERPEUTICS INC | $0 | – | -170,000 | -100.0% | -0.17% | – |
| VLRX | Exit | VALERITAS HOLDINGS INC | $0 | – | -1,325,000 | -100.0% | -0.21% | – |
| CNCE | Exit | CONCERT PHARMACEUTICALS INC | $0 | – | -105,656 | -100.0% | -0.66% | – |
| INCY | Exit | INCYTE CORP | $0 | – | -21,500 | -100.0% | -0.68% | – |
| TBIO | Exit | TRANSLATE BIO INC | $0 | – | -228,939 | -100.0% | -0.85% | – |
| NXTM | Exit | NXSTAGE MEDICAL INC | $0 | – | -312,119 | -100.0% | -4.44% | – |
| LOXO | Exit | LOXO ONCOLOGY INC | $0 | – | -181,675 | -100.0% | -12.65% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.